Kornimate/medical-research-clean huggingface dataset:
causes of goiter in children attending assiut university children hospital

Conditions: Goiter

Summary: thyroid disorders are one of the most common endocrine problems in children and adolescents. diagnostic considerations can be approached from the perspective of the goiter.a goiter, or thyromegaly, is an enlargement of the thyroid gland.persons with enlarged thyroids can have normal function of the gland (euthyroidism), thyroid deficiency (hypothyroidism), or overproduction of the hormones (hyperthyroidism).

congenital goiter most commonly occurs in neonates born to mothers with known thyroid disease especially graves' disease. other causes of congenital goitrous hypothyroidism are thyroid dyshormonogenesis, endemic iodine deficiency and maternal goitrogen ingestion or iodine excess (expectorants, povidone iodine). the most common causes of euthyroid goiter in childhood are chronic lymphocytic thyroiditis and a colloid goiter (simple goiter). thyroid enlargement that is not caused by inflammatory, infectious or neoplastic causes is termed a colloid goiter, also. chronic lymphocytic thyroiditis , also known as hashimoto thyroiditis, is an autoimmune, inflammatory process that causes up to 55% to 65% of all euthyroid goiters, and almost all cases of thyroiditis in childhood and adolescence. a large north american prevalence study showed that as many as 1.2% of children aged 11 to18 years have chronic lymphocytic thyroiditis, as defined by an enlarged thyroid gland and detectable serum thyroid antibodies. thyroid nodules are relatively common in adolescents; these nodules are usually asymptomatic and often discovered incidentally, but they raise the fear of cancer. a multi-nodular goiter is almost invariably caused by hashimoto's thyroiditis and it carries a good prognosis. the asymptomatic, solitary thyroid nodule is a thyroid adenoma, thyroid carcinoma or a thyroid cyst. thyroid carcinoma occurs in approximately one per one million persons/year in the first-two decades of life. no reported data are found as regard of causes of goiter in children in our locality.

Eligibility criteria:
inclusion criteria: * children of both sexes of ages since birth up to 18 years old who are presented by goiter. exclusion criteria: * any patient with neck swelling other than goiter. * refusal of participation.

Keywords: goiter
acupuncture treatment for patients who develop arrhythmias in the post-operative cardio-thoracic setting

Conditions: Post-Operative Atrial Fibrillation; Acupuncture Therapy

Summary: a feasibility study on the provision of acupuncture treatment in the hospital to 20 patients who have undergone open heart surgery procedures. the acupuncture treatments may begin as early as postoperative day 2.

primary aim • evaluate the feasibility of providing acupuncture in the hospital setting for 20 patients undergoing open heart surgery and subsequently develop arrhythmias. secondary aims • evaluate the short-term effect of acupuncture including the effects on patient's arrhythmias, stress, anxiety, and pain measured by electrocardiogram monitoring and electrocardiography, vas scores, and wiwi questionnaire for the patient.

Eligibility criteria:
inclusion criteria: 1. patients who have undergone cabg and/or cardiac valve operations. 2. patients developing postoperative atrial fibrillation, and documented by ecg prior to acupuncture intervention, and treated with the common anti arrhythmic treatment of the department. 3. patients moving to the step-down unit on postoperative day 2 or later. 4. ability to provide informed consent. 5. ability to speak english and complete all aspects of this trial. 6. at least 18 years of age. exclusion criteria: 1. patients with any other cardiac or non-cardiac concomitant procedures. 2. patients with suspected sternal wound infection and/or with prolonged sternal wound dressing and wound- vac-system application or open chest wound. 3. patients with abnormal postoperative track staying in the intensive care unit for any clinical reason or hemodynamic compromise. 4. patients with platelet count \<50,000 5. patients in a severe immunocompromised state. 6. pregnant women. all patients who meet the criteria will have their medical records reviewed to ensure they are not pregnant.
immune cells phenotypes during covid-19

Conditions: Sars-CoV2; Innate Immunity; Immunization; Infection; Alveolar Lung Disease; Endothelial Dysfunction

Summary: the ongoing pandemic caused by the severe acute respiratory syndrome coronavirus 2 (sars cov-2) has infected more than one hundred twenty million peoples worldwide one year after its onset with a case-fatality rate of almost 2%. the disease due to the coronavirus 2019 (i.e., covid-19) is associated with a wide range of clinical symptoms. as the primary site of viral invasion is the upper respiratory airways, lung infection is the most common complication. most infected patients are asymptomatic or experience mild or moderate form of the disease (80 %). a lower proportion (15%) develop severe pneumonia with variable level of hypoxia that may required hospitalization for oxygen therapy. in the most severe cases (5%), patients evolve towards critical illness with organ failure such as the acute respiratory distress syndrome (ards). at this stage, invasive mechanical ventilation is required in almost 70 % and the hospital mortality rises to 37 %. immune cells are key players during sars cov-2 infection and several alterations have been reported including lymphocytes (t, b and nk) and monocytes depletion, and cells exhaustion. such alterations were much more pronounced in patients with the most severe form of the disease. beside, a dysregulated proinflammatory response has also been pointed out as a potential mechanism of lung damage. finally, covid-19 is associated with an unexpectedly high incidence of thrombosis which probably results from the viral invasion of endothelial cells. the investigators aim to explore prospectively the alterations of innate and adaptive immune cells during both the acute and the recovery phase of sars cov-2 pneumonia. flow and spectral cytometry will be used to perform deep subset profiling focusing on t, b, nk, nkt, gamma-gelta t, monocytes and dendritic cells. each specific cell type will be further characterized using markers of activation/inhibition, maturation/differenciation and senescence as well as chemokines receptors. t-cell memory specificity will be explore using specific sars cov-2 pentamer. platelet activation and circulating microparticles will be explore using flow cytometry. serum sars cov-2 antibodies (iga, igm, igg), serum cytokines, and serum biomarkers of alveolar epithelial and endothelial cells will be analyze using elisa and correlate with the severity of the disease.


Eligibility criteria:
inclusion criteria: * age \> 18 y * laboratory confirmed sars cov-2 infection (positive rt-pcr). * ground-glass opacity on chest computed-tomography * time from hospital admission to inclusion \< or equal to 72 h exclusion criteria: * pregnant * under legal restriction
prophylactic administration of levosimendan in patients undergoing coronary surgery

Conditions: Coronary Artery Disease

Summary: the present pilot study aims to investigate the effectiveness of the preoperative infusion of levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting.

myocardial revascularization in patients with impaired left ventricular function remains a serious problem in cardiac surgery. despite the recent developments with the use of new surgical techniques (mini-extracorporeal circulation, off pump surgery) the perioperative morbidity and mortality are relatively high. therapeutic solutions with the use of inotropic drugs, as adrenergic agonists and phosphodiesterase inhibitors, have offered important improvement to the hemodynamic status of these patients, but they have not considerably decreased mortality. these drugs owe their positive inotropic action to the increase of intracellular calcium and thereafter they improve the myocardial function. levosimendan (simdax) is a new calcium sensitizer which increases the myocardial contractility without particular promotion of the intracellular calcium accumulation. contemporary experimental and clinical data demonstrated the effectiveness of this drug in the reduction of surgical mortality to the patients with low left ventricular ejection fraction (lvef) who undergo coronary artery bypass grafting (cabg). this is an original prospective randomized controlled study focused on the preoperative use of this drug in patients with impaired left ventricular function which is associated with a high operative risk (i.e. euroscore). perioperative myocardial stunning is particularly evident in this cohort of patients. prophylactic administration of levosimendan the day before the operation could be translated in improved myocardial performance intraoperatively and during the early postoperative period.

Eligibility criteria:
inclusion criteria: * coronary artery disease which warrants myocardial revascularization with coronary artery bypass grafting according to current guidelines * age \< 79 years old * left ventricular ejection fraction \<= 40% * informed patient's consent exclusion criteria: * age \< 18 years old * emergency surgery * medical history of acute myocardial infarction with st elevation (stemi) less than 14 days old * any severe comorbidity which increases the perioperative risk (i.e. neoplasia, rheumatoid arthritis, chronic obstructive pulmonary disease) * need for valvular replacement surgery * redo surgery * serum creatinine \> 2 mg/dl * history of malignant cardiac arrhythmias

Keywords: coronary artery disease levosimendan coronary artery bypass grafting cardiac surgery
effects of ocular electroacupuncture on abducens nerve palsy

Conditions: Abducens Nerve Paralysis

Summary: the purpose of the study is to testify the efficacy of treating abducens nerve palsy with ocular electroacupuncture or ocular acupuncture, and to compare the efficacy between these two interventions.

the purpose of the study is to testify whether ocular electroacupuncture or ocular acupuncture is effective for abducens nerve palsy (anp), through treating anp patient for 6 weeks, using self-invented acupoints according to anatomy of extraocular muscles innervated by abducens nerve, and using sham acupuncture as controlled group, and try to provide clinical evidence for promoting these new techniques.

Eligibility criteria:
criteria: inclusion criteria; 1. patient with confirmed diagnosis of abducens nerve palsy made by neurologist or ophthalmologist; 2. patient in stable condition after treatment for primary disease; 3. age between 18 to 80 years old without gender limitation; 4. haven't received acupuncture intervention for anp before; 5. patient with conscious, willing to cooperate and voluntarily agreed to participate and signed informed consent forms. exclusion criteria: 1. those with other diagnosed medical conditions known to contribute to anp symptoms, such as thyroid disease, myasthenia gravis, mitochondrial myopathy, congenital strabismus or received strabismus surgery; 2. those with color blindness, dyschromatopsia or abnormal retinal correspondence couldn't complete computerized diplopia test; 3. those with serious medical conditions that might limit their participation; 4. those with eye or other location with serious infections; 5. women who had a positive pregnancy test or who were planning to become pregnant during the study period; 6. those with bleeding tendency, blood coagulation dysfunction or taken anticoagulant drugs; 7. who had participate in other clinical trials, which may affect the results.

Keywords: electroacupuncture abducens nerve palsy eyeball movement diplopia ocular motility disorder
observational retrospective cohort study of systemic therapies for r/r dlbcl

Conditions: Diffuse Large B Cell Lymphoma

Summary: to compare the efficacy outcomes of the l-mind cohort with the effectiveness in a matched patient population treated with systemic nccn/esmo guideline listed regimens administered in routine clinical care.

this retrospective observational cohort study aims to generate a historical control consisting of r/r dlbcl patients who received currently guideline recommended therapies.

Eligibility criteria:
eligibility criteria: 1. age ≥ 18 years at the initial dlbcl diagnosis. 2. one of the following histologically confirmed diagnosis: dlbcl not otherwise specified (nos); t-cell/histiocyte rich large b-cell lymphoma (thrlbcl); epstein-barr virus (ebv) positive dlbcl of the elderly (ebv-positive dlbcl), grade 3b follicular lymphoma (fl), composite lymphoma with a dlbcl component with a subsequent dlbcl relapse, according to the revised european american lymphoma/world health organization (real/who) classification. additionally, patients with the evidence of histological transformation to dlbcl from an earlier diagnosis of low grade lymphoma (i.e., an indolent pathology such as fl, marginal zone lymphoma, chronic lymphocytic leukemia) into dlbcl with a subsequent dlbcl relapse are also eligible. 3. relapsed or refractory dlbcl and received at least 2 systemic regimens for the treatment of dlbcl, including at least 1 anti-cd20 containing therapy. non-eligibility criteria: 1. patients with central nervous system (cns) involvement by lymphoma at initial dlbcl diagnosis. 2. patients who were treated with cd19-targeted therapy or immunomodulatory drugs (imids) (e.g., thalidomide, len) as a frontline dlbcl therapy. 3. patients who underwent an allogeneic stem cell transplant. 4. patients who had a prior history of malignancies other than dlbcl, unless the patient has been free of the disease for ≥5 years prior to inclusion. note: patients with the following malignancies within the 5 years period are still eligible: 1. basal cell carcinoma of the skin 2. squamous cell carcinoma of the skin 3. carcinoma in situ of the cervix 4. carcinoma in situ of the breast 5. carcinoma in situ of the bladder 6. incidental histological finding of prostate cancer (tumor/node/metastasis \[tnm\] stage of t1a or t1b) 5. patients who received tafasitamab.
non-interventional, postauthorization safety study of ventavis for pulmonary arterial hypertension (pah)

Conditions: Hypertension, Pulmonary

Summary: this study is collecting post-marketing information on the safety and effectiveness of ventavis under the routine clinical practice for patients with pah

this local, prospective, non-interventional, company sponsored, multi-center, single-cohort study includes patients treated with ventavis for pah. a total of 270 patients (valid for safety analysis) is planned to be enrolled in 5 years. target population is patients with pah diagnosis. this study is performed as an all-patient investigation, therefore all patients who receive ventavis treatment for pah need to be registered. the treatment should be performed based on the product label in japan. the standard observation period will last for 12 months from starting ventavis treatment. in addition, the extension observation will be carried out as long as ventavis treatment continues or at most for more 4 years. the standard observation points are 3 month and 1 to 5 years.

Eligibility criteria:
inclusion criteria: * patients diagnosed with pah * patients for whom the decision to initiate treatment with ventavis was made as per investigator's routine treatment practice. exclusion criteria: - n/a

Keywords: iloprost ventavis prostacycline analogue pulmonary arterial hypertension japan post-marketing surveillance
comparison of pilates exercises verses muscle energy techniques along with kinesio taping in non-specific low back pain

Conditions: Pilates Exercises With Kinesio Taping; Muscle Energy Techniques Along With Kinesio Taping

Summary: to compare the effects of pilates excercises versus muscle energy technique along with kinesiotaping in non specific low back pain.

this study will help to compare the effects of pilates exercises with kinesiotaping and on other hand the effects of muscle energy technique with kinesiotaping for improving pain, disability and range of motion in patient with non specific low back pain. by combining these interventions, time consumption for treatment and disability among community due to low back pain will be reduced. this treatment will be effective for participants for improving function, movement of joints and muscle to manage and treat low back pain. the combination of treatment will be more effective to relief non specific low back pain. the targeted population of 18-40 years old and most of them are having occupational related low back pain or due to bad posture, study will have an impact in improving and managing the low back pain in such population.

Eligibility criteria:
inclusion criteria: * subjects of both genders should present with non-specific low back pain and between 18 and 40 years of age.(21) * could maintain their standing posture independently for _\>30s. * patient having enough physical autonomy to participate in the physical activities required by the study. * the patient having a visual analog scale (vas) score of equal to or \>3 will be included.(16). exclusion criteria: * a history of spinal surgery, compression fracture, spondylolisthesis, or sciatica, ongoing pregnancy, experiencing hypertension, cardiovascular disease, diabetes mellitus, liver disease, renal disease, rheumatoid arthritis, or other rheumatologically related pathologies (8). * those taking corticosteroids 2 weeks before recruitment. * hypersensitivity to the tape(6).
ankle trauma in children, application of ottawa ankle rules from 5 years old, what is the impact

Conditions: Sports Injuries in Children

Summary: ankle sprain in children is a very common pathology. currently in france, a standard x-ray is done in almost all cases. however, the literature has for several years validated the consideration of the ottawa ankle rules in children to avoid the realization of these x-rays. our study is an evaluation of clinical practice. the aim is to assess the impact of the implementation of a new protocol using the ottawa ankle rules from the age of 5. in particular, radiographic sparing and absence of diagnostic error.

main objective: to compare the rate of x-rays performed before and after implementation of the protocol in pediatric emergencies. secondary objectives (if applicable): * compare the time spent in the emergency room of patients before and after implementation of the protocol * evaluate the gain in terms of cost for the healthcare system * evaluate the adherence of caregivers to compliance with the protocol * evaluate the decrease in the rate of x-rays performed in different age groups. * evaluation of the consultation rate in the month for the same reason primary endpoint = x-ray rate as a % of x-rays performed on the number of children presenting to pediatric emergencies over the period studied (before implementation of the protocol in a similar period = may to october 2022 / after implementation of the protocol = may to october 2023) secondary endpoints = * time spent in the emergency room in min * estimation of the cost for the healthcare system by taking the cost of an x-ray and evaluating the gain on the reduction in the rate of x-rays performed (number of x-rays - cost of an x-ray) * evaluation of caregiver compliance by measuring the number of x-rays performed outside the protocol (x-ray performed despite the absence of ottawa criteria) * x-ray rate by age group * spontaneous reconsultation rate within 1 month

Eligibility criteria:
inclusion criteria: * 5 to 18 years old * consulting in pediatric emergency in nancy children hospital * for ankle injury exclusion criteria: constitutional bone disease polytrauma inability to assess the patient (inebriated, altered consciousness, neurosensitive disease, intoxication) non-acquired walking injury more than 10 days old patient re-consults for the same injury previously assessed in the same centre patient with previous radiographs prior to consultation open fracture sensory or vascular deficit haemophilia metabolic disease with proven osteopenia

Keywords: ankle children ottawa
effect of whole body electromyostimulation and/or protein supplementation on sarcopenic obesity in 70+

Conditions: Sarcopenic Obesity

Summary: the aim of the study is to determine the effect of 16 weeks of whole body-electromyostimulation (wb-ems) and/or protein supplementation on sarcopenic obesity (so) in community dwelling male subjects 70+ with so . 108 eligible men will be randomly assigned to either a (1) wb-ems and protein (2) protein (3) sedentary control group. wb-ems will be applied 1,5 x 20 min per week (i.e. 3 sessions in two weeks) with bipolar current, 85 hz in an intermitted mode (4 s - 4 s of rest). protein supplementation will be adjusted to dietary intake in order to reach a total protein intake between 1,5 - 1,7g/kg body-mass/d . primary study endpoint will be the sarcopenia z-score

the aim of the study is to evaluate the effects of whole-body electromyostimulation (wb-ems) with additional protein supplementation on sarcopenic obesity parameters in independently living men 70 years and older with sarcopenic obesity. the randomized controlled study compares three groups with 36 subjects each: (1) wb-ems with additional protein supplementation, (2) protein-only and (3) passive control group, over a period of 16 weeks of wb-ems -training. group (1) conducts 1.5-times/week a 20 minute-sessions of wb-ems with additional protein, group (2) is limited to protein supplementation (only) and group (3) is constrained to maintain their habitual living behavior and physical activity. based on an individual nutrition analysis the protein intake will be adjusted to 1.5-1.7 g/kg/ bodymass/d. all groups will be supplemented with a maximum of 800 ie vitamin d. primary study endpoint will be changes of the sarcopenia z-score with skeletal muscle mass assessed via bio-impedance analysis (bia). secondary study endpoints are changes of obesity (i.e. body-fat as assessed via bia), cardiometabolic risk (i.e. metabolic syndrome z-score), strength parameters evaluated via dr. wolff backcheck and physiomed legpress, quality of life (sf-12) and functional disability (late life physical disability index).

Eligibility criteria:
inclusion criteria: * community dwelling, independent living men * sarcopenia * obesity (body fat \>=25%) exclusion criteria: * exclusion criteria for wb-ems-application (e.g. cardiac pacemaker) * diseases/medication that affect the study endpoints (e.g. glucocorticoids \>5mg/d) * absence of more than 2 weeks during the study period

Keywords: sarcopenia obesity whole-body electromyostimulation protein supplementation community dwelling men
assessment of afp and pivka-ii as prognostic indicators in liver transplantation for hepatocellular carcinoma

Conditions: Liver Transplantation; Hepatocellular Carcinoma; Alpha-Fetoprotein; Protein Induced by Vitamin K Absence or Antagonist-II

Summary: as key biomarkers in hcc, afp and pivka-ii reflects biological features of tumor and has been widely applied for clinical diagnosis. previous studies reported preoperative afp and pivka-ii are related to hcc recipient long-term survival after liver transplantation. however, there is no prospective study supporting these conclusions. this study aims to prospective collect liver transplantation cases from multiple transplant centers and further evaluate the prognostic role of preoperative afp and pivka-ii in liver transplantation for hcc.


Eligibility criteria:
inclusion criteria: 1. diagnosis of hcc based on ct or mri imaging or needle biopsy confirming a histologic diagnosis of hcc. 2. patients undergoing deceased donor liver transplantation for the first time. exclusion criteria: (1) patients who received split lt or simultaneous transplantation, (2) patients who received re-transplantation, (3) patients with macroscopic portal vein tumor thrombosis or other macrovascular invasion, (4) patients with incomplete follow-up, (5) taking warfarin at the time of lt biomarker measurements